Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …

Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …

A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant, BA.
2.86, has emerged and spread to numerous countries worldwide, raising alarm because its …

Background The monoclonal-antibody combination AZD7442 is composed of tixagevimab
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …

In late 2022, various Omicron subvariants emerged and cocirculated worldwide. These
variants convergently acquired amino acid substitutions at critical residues in the spike …

Omicron subvariants continuingly challenge current vaccination strategies. Here, we
demonstrate nearly complete escape of the XBB. 1.5, CH. 1.1, and CA. 3.1 variants from …

Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …

SARS-CoV-2 variants acquire mutations in the spike protein that promote immune evasion
and affect other properties that contribute to viral fitness, such as ACE2 receptor binding and …

Summary The SARS-CoV-2 Omicron variant has evolved into four sub-lineages—BA. 1, BA.
1.1, BA. 2, and BA. 3—with BA. 2 becoming dominant worldwide. We and others have …

The novel coronavirus disease (COVID-19) pandemic remains a global public health crisis,
presenting a broad range of challenges. To help address some of the main problems, the …